MarketPulse
B

$BEAM

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna Bolsters Board With Beam, Karuna Executives Ahead of Cell Therapy Launch

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.
BMYCELGrKYTXBEAMclinical developmentautoimmune diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics Secures $500M Credit Facility to Fund Sickle Cell Therapy Launch

Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.
BEAMcommercializationsickle cell disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics to Unveil 2025 Results and Novel Liver Disease Program

Beam Therapeutics will discuss 2025 results and unveil a new liver disease program on February 24, 2026. The company also secured FDA alignment for accelerated approval of BEAM-302.
BEAMFDA approvalbase editing